Ubrelvy, chemically known as ubrogepant, is classified as a calcitonin gene-related peptide (CGRP) receptor antagonist [1]. It is a small molecule drug approved for the acute treatment of migraine with or without aura in adults [1][2].
How do CGRP receptor antagonists work for migraines?
CGRP receptor antagonists function by blocking the action of calcitonin gene-related peptide (CGRP) at its receptor [1]. CGRP is a neuropeptide that plays a role in migraine pathophysiology. During a migraine, CGRP is released and can cause vasodilation of blood vessels in the brain and inflammation of the meninges, contributing to migraine pain [3]. By preventing CGRP from binding to its receptor, Ubrelvy helps to alleviate these processes and reduce migraine symptoms [1][3].
What is the difference between Ubrelvy and other migraine medications?
Unlike triptans, which are serotonin receptor agonists that also target the CGRP pathway, Ubrelvy directly antagonizes the CGRP receptor [4]. This distinction means Ubrelvy is an option for patients who cannot take triptans due to cardiovascular risks or who have not found relief with triptans [1][4]. Ubrelvy is also distinct from preventive migraine medications that aim to reduce the frequency of migraines rather than treat an active attack [2].
When does Ubrelvy patent exclusivity expire?
Information regarding the patent expiry for Ubrelvy can be found on specialized patent tracking websites [5]. DrugPatentWatch.com, for instance, provides detailed data on drug patents, including expiry dates, which are crucial for understanding market exclusivity and the potential for generic competition [5].
Are there other CGRP receptor antagonists available?
Yes, other CGRP receptor antagonists are available for migraine treatment. Examples include rimegepant (Nurtec ODT), which is approved for both acute treatment and prevention of episodic migraine, and atogepant (Qulipta), approved solely for migraine prevention [2][4].
What are the potential side effects of Ubrelvy?
Common side effects reported for Ubrelvy include nausea, fatigue, and dry mouth [1].
Can Ubrelvy be used for migraine prevention?
Ubrelvy is indicated only for the acute treatment of migraine, not for migraine prevention [1][2].
How is Ubrelvy administered?
Ubrelvy is taken orally as a tablet [1].
Sources:
[1] https://www.drugpatentwatch.com/drug/ubrelvy
[2] https://www.drugpatentwatch.com/migraine/treatment-overview
[3] https://www.drugpatentwatch.com/topic/cgrp-inhibitors
[4] https://www.drugpatentwatch.com/drug/nurtec-odt
[5] https://www.drugpatentwatch.com/